AstraZeneca and J&J Vie to Dominate New Era in Lung-Cancer Care

A rivalry is heating up between AstraZeneca Plc and Johnson & Johnson in lung cancer.

The US company’s new drug combination beat Astra’s best-seller Tagrisso in a study presented on Monday at Europe’s biggest cancer conference. But the UK drugmaker’s earlier rival findings show Tagrisso can be made effective when paired with chemotherapy.

J&J executives arguedthe findings would usher in a new era for lung-cancer care. Doctors at the conference said there isn’t a clear winner because they will need to make decisions for each patient based on side effects, benefits and ease of care.

“There’s not going to ...